Login Register Cart 0
Research Article

中华支睾吸虫肝吸虫CsHscB改善硬化性胆管炎小鼠模型中的胆汁淤积性肝纤维化

卷 24, 期 4, 2024

发表于: 17 May, 2023

页: [505 - 515] 页: 11

弟呕挨: 10.2174/1566524023666230418111949

价格: $65

conference banner
摘要

背景:原发性硬化性胆管炎(PSC)是一种以炎性纤维化为特征的慢性胆汁淤积性肝病，通常累及整个胆道。然而，治疗这种疾病的治疗方法非常有限。我们前期的研究发现，肝吸虫华支睾吸虫的脂质蛋白rCsHscB具有完全的免疫调节能力。因此，我们研究了rCsHscB在外源药物3,5-二氧羰基-1,4-二氢碰撞碱(DDC)诱导的硬化性胆管炎小鼠模型中的作用，以探讨该蛋白是否对PSC具有潜在的治疗价值。 方法:小鼠灌胃0.1% DDC，灌胃4周后给予CsHscB (30 μg/只，腹腔注射，3 d 1次);对照组在正常饮食条件下给予等量PBS或CsHscB。4周处死小鼠，观察胆道增生、纤维化和炎症情况。 结果:rCsHscB治疗可减轻ddc诱导的肝充血和肝肿大，显著降低血清AST和ALT水平上调。与单独喂食DDC的小鼠相比，给DDC喂食rCsHscB显著降低了胆管细胞的增殖和促炎细胞因子的产生。此外，rCsHscB治疗显示肝脏α-SMA和其他肝纤维化标志物(马松染色、羟脯氨酸含量和胶原沉积)的表达降低。更有趣的是，经rCsHscB处理的ddc喂养的小鼠PPAR-γ表达显著上调，与对照小鼠相似，这表明PPAR-γ信号参与了rCsHscB的保护作用。 结论:总体而言，我们的数据显示rCsHscB可减缓DDC诱导的胆汁淤积性纤维化的进展，并支持操纵寄生虫衍生分子治疗某些免疫介导疾病的潜力。

关键词: CsHscB蛋白，华支睾吸虫，DDC，胆汁淤积性肝纤维化，PPAR-γ，免疫调节。

« Previous Next »
[1]
Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet 2018; 391(10139): 2547-59.
[http://dx.doi.org/10.1016/S0140-6736(18)30300-3] [PMID: 29452711]
[2]
Iwaisako K, Jiang C, Zhang M, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci 2014; 111(32): E3297-305.
[http://dx.doi.org/10.1073/pnas.1400062111] [PMID: 25074909]
[3]
Fickert P, Stöger U, Fuchsbichler A, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 2007; 171(2): 525-36.
[http://dx.doi.org/10.2353/ajpath.2007.061133] [PMID: 17600122]
[4]
Mariotti V, Strazzabosco M, Fabris L, Calvisi DF. Animal models of biliary injury and altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis 2018; 1864(4) (4 Pt B): 1254-61.
[http://dx.doi.org/10.1016/j.bbadis.2017.06.027] [PMID: 28709963]
[5]
Sawant DV, Gravano DM, Vogel P, Giacomin P, Artis D, Vignali DAA. Regulatory T cells limit induction of protective immunity and promote immune pathology following intestinal helminth infection. J Immunol 2014; 192(6): 2904-12.
[http://dx.doi.org/10.4049/jimmunol.1202502] [PMID: 24532574]
[6]
Stiemsma L, Reynolds L, Turvey S, Finlay B. The hygiene hypothesis: Current perspectives and future therapies. ImmunoTargets Ther 2015; 4: 143-57.
[http://dx.doi.org/10.2147/ITT.S61528] [PMID: 27471720]
[7]
Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology 2005; 128(4): 825-32.
[http://dx.doi.org/10.1053/j.gastro.2005.01.005] [PMID: 15825065]
[8]
Sandborn WJ, Elliott DE, Weinstock J, et al. Randomised clinical trial: The safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther 2013; 38(3): 255-63.
[http://dx.doi.org/10.1111/apt.12366] [PMID: 23730956]
[9]
Huang X, Zeng LR, Chen FS, Zhu JP, Zhu MH. Trichuris suis ova therapy in inflammatory bowel disease. Medicine 2018; 97(34): e12087.
[http://dx.doi.org/10.1097/MD.0000000000012087] [PMID: 30142867]
[10]
Croese J, O’neil J, Masson J, et al. A proof of concept study establishing Necator americanus in Crohn’s patients and reservoir donors. Gut 2006; 55(1): 136-7.
[http://dx.doi.org/10.1136/gut.2005.079129] [PMID: 16344586]
[11]
Helmby H. Human helminth therapy to treat inflammatory disorders- where do we stand? BMC Immunol 2015; 16(1): 12.
[http://dx.doi.org/10.1186/s12865-015-0074-3] [PMID: 25884706]
[12]
Yordanova IA, Ebner F, Schulz AR, et al. The worm-specific immune response in multiple sclerosis patients Receiving controlled trichuris suis ova immunotherapy. Life 2021; 11(2): 101.
[http://dx.doi.org/10.3390/life11020101] [PMID: 33572978]
[13]
McSorley HJ, Maizels RM. Helminth infections and host immune regulation. Clin Microbiol Rev 2012; 25(4): 585-608.
[http://dx.doi.org/10.1128/CMR.05040-11] [PMID: 23034321]
[14]
Wang L, Xie H, Xu L, et al. rSj16 Protects against DSS-Induced Colitis by Inhibiting the PPAR-α Signaling Pathway. Theranostics 2017; 7(14): 3446-60.
[http://dx.doi.org/10.7150/thno.20359] [PMID: 28912887]
[15]
Nascimento Santos L, Carvalho Pacheco LG, Silva Pinheiro C, Alcantara-Neves NM. Recombinant proteins of helminths with immunoregulatory properties and their possible therapeutic use. Acta Trop 2017; 166: 202-11.
[http://dx.doi.org/10.1016/j.actatropica.2016.11.016] [PMID: 27871775]
[16]
Zhang BB, Yan C, Fang F, et al. Increased hepatic Th2 and Treg subsets are associated with biliary fibrosis in different strains of mice caused by Clonorchis sinensis. PLoS One 2017; 12(2): e0171005.
[http://dx.doi.org/10.1371/journal.pone.0171005] [PMID: 28151995]
[17]
Yan C, Fang F, Zhang YZ, et al. Recombinant CsHscB of carcinogenic liver fluke Clonorchis sinensis induces IL-10 production by binding with TLR2. PLoS Negl Trop Dis 2020; 14(10): e0008643.
[http://dx.doi.org/10.1371/journal.pntd.0008643] [PMID: 33044969]
[18]
Won KY, Kim GY, Kim YW, Song JY, Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol 2010; 41(1): 107-12.
[http://dx.doi.org/10.1016/j.humpath.2009.07.006] [PMID: 19762066]
[19]
Wu H, Chen C, Ziani S, et al. Fibrotic events in the progression of cholestatic liver disease. Cells 2021; 10(5): 1107.
[http://dx.doi.org/10.3390/cells10051107] [PMID: 34062960]
[20]
Mariotti V, Cadamuro M, Spirli C, Fiorotto R, Strazzabosco M, Fabris L. Animal models of cholestasis: An update on inflammatory cholangiopathies. Biochim Biophys Acta Mol Basis Dis 2019; 1865(5): 954-64.
[http://dx.doi.org/10.1016/j.bbadis.2018.07.025] [PMID: 30398152]
[21]
Sharma S, Rana S, Patial V, Gupta M, Bhushan S, Padwad YS. Antioxidant and hepatoprotective effect of polyphenols from apple pomace extract via apoptosis inhibition and Nrf2 activation in mice. Hum Exp Toxicol 2016; 35(12): 1264-75.
[http://dx.doi.org/10.1177/0960327115627689] [PMID: 26811344]
[22]
Fickert P, Thueringer A, Moustafa T, et al. The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. Lab Invest 2010; 90(6): 844-52.
[http://dx.doi.org/10.1038/labinvest.2010.61] [PMID: 20368698]
[23]
Nishio T, Hu R, Koyama Y, et al. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. J Hepatol 2019; 71(3): 573-85.
[http://dx.doi.org/10.1016/j.jhep.2019.04.012] [PMID: 31071368]
[24]
Dewidar B, Meyer C, Dooley S, Meindl-Beinker AN. TGF-β in hepatic stellate cell activation and liver fibrogenesis—updated 2019. Cells 2019; 8(11): 1419.
[http://dx.doi.org/10.3390/cells8111419] [PMID: 31718044]
[25]
Ma T, Cai X, Wang Z, et al. miR-200c accelerates hepatic stellate cell-induced liver fibrosis via targeting the FOG2/PI3K pathway. BioMed Res Int 2017; 2017: 1-8.
[http://dx.doi.org/10.1155/2017/2670658] [PMID: 28691020]
[26]
Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGFβ1 in initiating hepatic stellate cell activation in vivo. J Hepatol 1999; 30(1): 77-87.
[http://dx.doi.org/10.1016/S0168-8278(99)80010-5] [PMID: 9927153]
[27]
Liu X, Xu J, Rosenthal S, et al. Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution. Gastroenterology 2020; 158(6): 1728-1744.e14.
[http://dx.doi.org/10.1053/j.gastro.2020.01.027] [PMID: 31982409]
[28]
Hazra S, Xiong S, Wang J, et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004; 279(12): 11392-401.
[http://dx.doi.org/10.1074/jbc.M310284200] [PMID: 14702344]
[29]
Zhang F, Kong D, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: From bench to bedside. Cell Mol Life Sci 2013; 70(2): 259-76.
[http://dx.doi.org/10.1007/s00018-012-1046-x] [PMID: 22699820]
[30]
Zhang F, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal 2012; 24(3): 596-605.
[http://dx.doi.org/10.1016/j.cellsig.2011.11.008] [PMID: 22108088]
[31]
Vetuschi A, Pompili S, Gaudio E, Latella G, Sferra R. PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD. Eur Rev Med Pharmacol Sci 2018; 22(24): 8839-48.
[PMID: 30575926]
[32]
Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275(46): 35715-22.
[http://dx.doi.org/10.1074/jbc.M006577200] [PMID: 10969082]
[33]
Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006; 350(2): 385-91.
[http://dx.doi.org/10.1016/j.bbrc.2006.09.069] [PMID: 17010940]
[34]
Planagumà A, Clària J, Miquel R, et al. The selective cyclooxygenase‐2 inhibitor SC‐236 reduces liver fibrosis by mechanisms involving non‐parenchymal cell apoptosis and PPARγ activation. FASEB J 2005; 19(9): 1120-2.
[http://dx.doi.org/10.1096/fj.04-2753fje] [PMID: 15876570]
[35]
Li J, Guo C, Wu J. The agonists of peroxisome proliferator-activated receptor-γ for liver fibrosis. Drug Des Devel Ther 2021; 15: 2619-28.
[http://dx.doi.org/10.2147/DDDT.S310163] [PMID: 34168433]
[36]
Wu L, Guo C, Wu J. Therapeutic potential of PPARγ natural agonists in liver diseases. J Cell Mol Med 2020; 24(5): 2736-48.
[http://dx.doi.org/10.1111/jcmm.15028] [PMID: 32031298]
[37]
Choi MJ, Park JS, Park JE, Kim HS, Kim HS. Galangin suppresses pro-inflammatory gene expression in polyinosinic-polycytidylic acid-stimulated microglial cells. Biomol Ther 2017; 25(6): 641-7.
[http://dx.doi.org/10.4062/biomolther.2017.173] [PMID: 29081092]

Rights & Permissions Print Cite
Article Metrics
30
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy